» Articles » PMID: 30524906

MiR-17-5p-CXCL14 Axis Related Transcriptome Profile and Clinical Outcome in Diffuse Gliomas

Overview
Journal Oncoimmunology
Date 2018 Dec 8
PMID 30524906
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

GBM tissues are comprised of not only tumor cells but also tumor-associated nontumor cells, such as stromal cells and immune cells, which dilute the purity of glioma cells and function in glioma biology. However, the roles of miRNAs in modulating glioma purity are not clarified. In total, 838 glioma samples with transcriptome data, including 537 RNAseq data from TCGA project and 301 microarray data from Chinese Glioma Genome Atlas (CGGA project), were recruited into our investigation. Tumor purity, molecular subtypes and IDH status were also available. R language was employed as the main tool for statistical analysis and graphical work. Screening miRNA profiling and paired TCGA samples' transcriptome data demonstrates that miR-17-5p expression harbors the most significant positive correlation with glioma purity among all miRNAs. CXCL14 shows robust negative correlation with miR-17-5p expression in TCGA and CGGA dataset. miR-17-5p directly targets CXCL14 and functions as a tumor-suppressor of GBM. CXCL14 showed lower expression in proneural subtype and may contribute as a potential marker for proneural subtype in glioma. Genes markedly correlated with CXCL14 are involved in essential functions associated with anti-tumor immune process. CXCL14 has a strong correlation with immune(T cells, Monocytic lineage and Neutrophils) and Fibroblasts within glioma environment. miR-17-5p and CXCL14 exhibited predictive values for high-grade glioma(HGG) patients: Higher miR-17-5p indicated significantly longer survival while lower CXCL14 indicated longer survival. Our results highlight the importance of the miR-17-5p-CXCL14 axis in regulating key steps of anti-tumor immune process and may serve as potential targets of immune treatments for gliomas.

Citing Articles

The LINC00957/miR-17-5p axis regulates the cell cycle and migration in glioblastoma via the cuproptosis-related gene nephronectin.

Duan R, Zhao X, Hong Z, Yu L Transl Cancer Res. 2024; 13(9):4923-4937.

PMID: 39430842 PMC: 11483365. DOI: 10.21037/tcr-24-450.


Emerging roles of ferroptosis-related miRNAs in tumor metastasis.

Jiang Z, Zhou J, Deng J, Li L, Wang R, Han Y Cell Death Discov. 2023; 9(1):193.

PMID: 37369681 PMC: 10300116. DOI: 10.1038/s41420-023-01486-y.


Hypoxia-induced CXC chemokine ligand 14 expression drives protumorigenic effects through activation of insulin-like growth factor-1 receptor signaling in glioblastoma.

Wei S, Chiang J, Wang H, Lei F, Huang Y, Wang C Cancer Sci. 2022; 114(1):174-186.

PMID: 36106406 PMC: 9807529. DOI: 10.1111/cas.15587.


The identification of miRNA and mRNA expression profiles associated with pediatric atypical teratoid/rhabdoid tumor.

Xu X, Yuan H, Pan J, Chen W, Chen C, Li Y BMC Cancer. 2022; 22(1):499.

PMID: 35524230 PMC: 9074338. DOI: 10.1186/s12885-022-09549-6.


A miR-129-5P/ARID3A Negative Feedback Loop Modulates Diffuse Large B Cell Lymphoma Progression and Immune Evasion Through Regulating the PD-1/PD-L1 Checkpoint.

Zheng W, Lai G, Lin Q, Issah M, Fu H, Shen J Front Cell Dev Biol. 2021; 9:735855.

PMID: 34778251 PMC: 8579866. DOI: 10.3389/fcell.2021.735855.


References
1.
Benarafa C, Wolf M . CXCL14: the Swiss army knife chemokine. Oncotarget. 2015; 6(33):34065-6. PMC: 4741434. DOI: 10.18632/oncotarget.6040. View

2.
Shurin G, Ferris R, Ferris R, Tourkova I, Perez L, Lokshin A . Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol. 2005; 174(9):5490-8. DOI: 10.4049/jimmunol.174.9.5490. View

3.
Shea A, Harish V, Afzal Z, Chijioke J, Kedir H, Dusmatova S . MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Cancer Med. 2016; 5(8):1917-46. PMC: 4971921. DOI: 10.1002/cam4.775. View

4.
Luo H, Chen Z, Wang S, Zhang R, Qiu W, Zhao L . c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma. Brain. 2015; 138(Pt 12):3654-72. DOI: 10.1093/brain/awv287. View

5.
Wang X, Shi Z, Wang X, Cao L, Wang Y, Zhang J . MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. J Cancer Res Clin Oncol. 2011; 138(4):573-84. DOI: 10.1007/s00432-011-1114-x. View